Glenmark Pharmaceuticals Ltd.

View in App
785.90 -16.35 ▼-2.0%

25 September 2023, 04:01:00 PM
Volume: 37,134

Company Profile

View details >>
Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.glenmarkpharma.com
Market Cap 22,175.60 Cr.
Enterprise Value(EV) 25,053.62 Cr. 2023-03
Financial Indicators
Earnings per share (EPS) 9.02 Trailing Twelve Months Ending 2023-06
Price-Earning Ratio (PE) 87.08 Trailing Twelve Months Ending 2023-06
Industry PE 37.43 Trailing Twelve Months Ending 2023-06
Book Value / Share 341.27 Trailing Twelve Months Ending 2023-06
Price to Book Value 2.30 Calculated using Price: 785.90
Dividend Yield 0.32 Period Ending 2023-03
No. of Shares Subscribed 28.22 Cr. 282,168,156 Shares
FaceValue 1
About Glenmark Pharmaceuticals Ltd.
The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark's ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark's formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology.

Glenmark Pharmaceuticals Ltd. Delivery

View details >>
Delivered Qty
Traded Qty

Glenmark Pharmaceuticals Ltd. Performance

View details >>
1 Day
-2.04%
1 Week
-8.19%
1 Month
+3.53%
3 Month
+25.27%
6 Month
+80.11%
1 Year
+102.53%
2 Year
+53.54%
5 Year
+19.96%
10 Year
+49.65%

Glenmark Pharmaceuticals Ltd. Fundamental Ratios

View details >>
9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 8.79 27.46 27.31 16.67 17.21 13.32 14.81 12.33 4.07
Return on Capital Employed (%) 12.40 18.53 20.54 14.77 16.47 14.04 15.30 14.19 9.17
Return on Assets (%) 2.58 8.52 11.33 7.40 7.98 6.17 7.11 6.74 2.29

Glenmark Pharmaceuticals Ltd. Balance Sheet

View details >>
Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Shh. Funds 2,983 1,783 3,630 4,493 5,163 5,605 6,071 7,065 9,087 9,474
Non Curr. Liab. 1,967 2,749 1,499 3,258 2,824 2,280 3,033 2,804 1,270 2,681
Curr. Liab. 2,949 3,777 3,999 2,703 3,288 4,021 4,126 4,201 4,689 5,046
Minority Int. 13 0 0 0 0 0 0 0 351 365
Equity & Liab. 7,912 8,309 9,128 10,453 11,275 11,906 13,229 14,069 15,397 17,566
Non Curr. Assets 3,150 2,978 3,224 3,578 4,286 5,209 6,425 6,709 7,115 7,692
Curr. Assets 4,763 5,331 5,904 6,875 6,989 6,697 6,804 7,360 8,282 9,874
Misc. Exp. not W/O
Total Assets 7,912 8,309 9,128 10,453 11,275 11,906 13,229 14,069 15,397 17,566

Glenmark Pharmaceuticals Ltd. Profit and Loss

View details >>
Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-06 Rs. Cr. TTM
Net Sales 6,681 7,562 9,079 9,074 9,865 10,641 10,944 12,305 12,990 13,614
Other Income 7 20 37 91 208 160 50 167 317 155
Total Income 6,688 7,582 9,117 9,166 10,074 10,801 10,994 12,472 13,307 13,769
Total Expenditure -5,467 -6,125 -7,043 -7,459 -8,280 -8,943 -8,860 -9,985 -10,712 -11,136
PBIDT 1,221 1,457 2,074 1,707 1,794 1,858 2,135 2,487 2,595 2,632
Interest -190 -179 -237 -286 -335 -377 -353 -298 -350 -402
Depreciation -300 -234 -264 -302 -326 -417 -444 -487 -611 -619
Taxation -334 -301 -383 -315 -376 -320 -412 -448 -491 -454
Exceptional Items -187 -81 167 33 45 -261 -766 -818
PAT 209 743 1,109 804 925 776 970 994 377 339
Minority Interest 0 0 0 0 0 0 -52 -80 -85
Share Associate
Other Related Items
Consolidated Net Profit 210 743 1,109 804 925 776 970 942 297 255
Adjusted EPS 8 26 39 28 33 28 34 33 11 9

Glenmark Pharmaceuticals Ltd. Cash Flow

View details >>
Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 854 482 345 657 1,648 1,324 1,392 1,131 1,109 625
Cash Fr. Inv. -368 -540 -880 -712 -1,013 -699 -784 -675 -333 -528
Cash Fr. Finan. -98 199 699 543 -469 -739 -445 -442 -520 -77
Net Change 388 141 163 488 166 -114 164 14 255 19
Cash & Cash Eqvt 795 764 857 1,056 1,233 936 1,110 1,138 1,411 1,443

Glenmark Pharmaceuticals Ltd. Shareholding Pattern

View details >>
9 Qtrs 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%)
Promoter 46.63 46.65 46.65 46.65 46.65 46.65 46.65 46.65 46.65
Public 53.37 53.35 53.35 53.35 53.35 53.35 53.35 53.35 53.35
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Glenmark Pharmaceuticals Ltd. Announcements

View details >>
Sat, 23 Sep 2023
Announcement under Regulation 30 (LODR)-Credit Rating
India Ratings has discontinued and withdrawn the outstanding voluntary issuer ratings disclosure due to regulatory requirements.
Fri, 22 Sep 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Details of Analyst/ Investors Meeting is attached
Thu, 21 Sep 2023
Clarification sought from Glenmark Pharmaceuticals Ltd
The Exchange has sought clarification from Glenmark Pharmaceuticals Ltd on September 21 2023 with reference to news appeared inwww.moneycontrol.com dated September 21 2023 quoting "Glenmark Life Sciences gains on parent Glenmark Pharma plan to pare stake"

The reply is awaited.

Glenmark Pharmaceuticals Ltd. Technical Scans

View details >>
Mon, 25 Sep 2023
Close Within 52 Week High Zone Close Within 52 Week High Zone
High Increase in 1 Month High Increase in 1 Month
High Increase in 3 Months High Increase in 3 Months
High Increase in 6 Months High Increase in 6 Months
High Increase in 1 Year High Increase in 1 Year

Glenmark Pharmaceuticals Ltd. Related Stocks

View details >>
  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 269,697.25 1,124.05 -0.7%
Divi's Laboratories Ltd. 99,021.11 3,730.05 +0.6%
Cipla Ltd. 95,166.58 1,180.05 -0.6%
Dr. Reddy's Laboratories Ltd. 90,720.90 5,439.40 -1.4%
Apollo Hospitals Enterprise Ltd. 73,268.35 5,095.45 +2.2%
Mankind Pharma Ltd. 69,694.38 1,739.80 -0.7%
Torrent Pharmaceuticals Ltd. 62,519.33 1,844.85 -0.3%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-06 31.97 1,124.05 -0.7%
Divi's Laboratories Ltd. Consolidated 2023-06 67.03 3,730.05 +0.6%
Cipla Ltd. Consolidated 2023-06 30.62 1,180.05 -0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-06 19.21 5,439.40 -1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-06 109.58 5,095.45 +2.2%
Mankind Pharma Ltd. Consolidated 2023-03 54.37 1,739.80 -0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-06 49.55 1,844.85 -0.3%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-06 4.65 1,124.05 -0.7%
Divi's Laboratories Ltd. Consolidated 2023-06 7.55 3,730.05 +0.6%
Cipla Ltd. Consolidated 2023-06 3.91 1,180.05 -0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-06 3.70 5,439.40 -1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-06 11.68 5,095.45 +2.2%
Mankind Pharma Ltd. Consolidated 2023-03 5.69 1,739.80 -0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-06 9.49 1,844.85 -0.3%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,124.05 -0.7%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,730.05 +0.6%
Cipla Ltd. Consolidated 2023-03 0.02 1,180.05 -0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 5,439.40 -1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 5,095.45 +2.2%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 1,739.80 -0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 1,844.85 -0.3%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,124.05 -0.7%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,730.05 +0.6%
Cipla Ltd. Consolidated 2023-03 12.85 1,180.05 -0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,439.40 -1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 5,095.45 +2.2%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 1,739.80 -0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 1,844.85 -0.3%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,124.05 -0.7%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,730.05 +0.6%
Cipla Ltd. Consolidated 2023-03 12.85 1,180.05 -0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,439.40 -1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 5,095.45 +2.2%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 1,739.80 -0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 1,844.85 -0.3%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,124.05 -0.7%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,730.05 +0.6%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,180.05 -0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 5,439.40 -1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 5,095.45 +2.2%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 1,739.80 -0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 1,844.85 -0.3%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,124.05 -0.7%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,730.05 +0.6%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,180.05 -0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 5,439.40 -1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 5,095.45 +2.2%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 1,739.80 -0.7%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 1,844.85 -0.3%

Glenmark Pharmaceuticals Ltd. FAQ's

What is Glenmark Pharma share price?
Can I buy Glenmark Pharma shares now?
What is the Dividend Yield of Glenmark Pharma?
What is the Market Cap of Glenmark Pharma?
What are the key metrics to analyse Glenmark Pharma?
What is the 52 Week High and Low of Glenmark Pharma?
What is the trend of Glenmark Pharma share price?